Structure-based development of a subtype-selective orexin 1 receptor antagonist.

Author: DrabekMatthäus, GmeinerPeter, GuneraJakub, HellmannJan, HübnerHarald, KolbPeter, KrausFrank, LangmeadChristopher J, PröllTheresa, RosenbaumDaniel M, WeikertDorothee, YinJie

Paper Details 
Original Abstract of the Article :
Orexins are neuropeptides that activate the rhodopsin-like G protein-coupled receptors OX1R and OX2R. The orexin system plays an important role in the regulation of the sleep-wake cycle and the regulation of feeding and emotions. The nonselective orexin receptor antagonist suvorexant has been the fi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7395530/

データ提供:米国国立医学図書館(NLM)

Unlocking the Secrets of Sleep and More: Subtype-Selective Orexin 1 Receptor Antagonists

The intricate dance of our sleep-wake cycle, our appetites, and even our emotions is orchestrated by a complex network of chemicals and receptors in our brains. Orexins, a pair of neuropeptides, play a crucial role in this symphony, activating two distinct receptors: OX1R and OX2R. This study takes us on an exciting journey into the realm of subtype-selective OX1R antagonists, delving into their potential therapeutic applications for a range of conditions, including insomnia, drug addiction, anxiety, pain, and obesity.

A Molecular Dance for Precision Therapy

The researchers, guided by the crystal structures of OX1R and OX2R, meticulously crafted ligands that selectively target the OX1R receptor, leaving the OX2R untouched. This molecular choreography is a testament to the power of structure-based drug design, allowing for precise manipulation of receptor interactions. The resulting antagonist, JH112, exhibits subnanomolar affinity for OX1R and a remarkable 75-fold selectivity over the OX2R subtype. It's like a carefully crafted key that unlocks the OX1R without disturbing the intricate machinery of the OX2R.

Hope on the Horizon for Multiple Conditions

The development of subtype-selective OX1R antagonists opens up exciting avenues for therapeutic intervention in various conditions. These antagonists could offer targeted relief from insomnia, potentially aiding in better sleep quality and daytime alertness. Their potential in managing drug addiction, anxiety, pain, and obesity is also being investigated, offering hope for improved treatment options in these complex areas. It's like having a finely tuned instrument for addressing a symphony of health challenges.

Dr. Camel's Conclusion

This study is a compelling demonstration of how meticulous scientific exploration can unlock the secrets of the brain's intricate pathways. By targeting the OX1R receptor with precision, researchers have created a new tool that could revolutionize the treatment of a variety of conditions. It's like finding a new oasis in the desert, offering a refreshing source of hope for those seeking better health and well-being. The future holds exciting possibilities for this research, and we can't wait to see what further discoveries await.

Date :
  1. Date Completed 2020-09-17
  2. Date Revised 2021-01-15
Further Info :

Pubmed ID

32669442

DOI: Digital Object Identifier

PMC7395530

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.